
GLP1 Weight Loss Shot Tracker
Zepbound,Wegovy,Ozempic,Lilly
About
This app helps individuals on GLP-1 weight loss medications track their doses, monitor weight and body measurements, log symptoms, and manage nutrition. It provides a private journal and generates reports for healthcare providers.
What's New in GLP1 Weight Loss Shot Tracker
1.13
September 24, 2026
Your all-in-one GLP-1 app for tracking medication, supporting weight management, and managing your type 2 diabetes routine. What’s new: • Performance improvements and more languages Enjoying the app? Please leave us a rating!
MoreDeveloper apps
FAQ
What medications does GLP1 support?
GLP1 supports 17 medications, including Ozempic®, Wegovy®, Mounjaro®, Zepbound®, Saxenda®, Victoza®, Trulicity®, Rybelsus®, Foundayo™, compounded semaglutide, and compounded tirzepatide.
How does GLP1 help track weight loss?
GLP1 allows you to log your weight and view trend charts over weeks and months. You can also add progress photos and track body measurements like waist, hips, and chest.
Can GLP1 help me understand my symptoms?
Yes, GLP1 allows you to log 11 types of symptoms with severity scores. This helps you spot patterns and bring a full history to your doctor's appointments.
Does GLP1 have ads?
No, GLP1 does not contain advertisements. It is a completely private app where your data stays on your iPhone.
What kind of reports can GLP1 generate?
GLP1 can generate a one-tap PDF export of your full history, including doses, weight, symptoms, and nutrition logs, which can be shared with your clinician.
Is GLP1 available on Android?
Currently, GLP1 is only supported on iPhones. It is designed to keep your data private on your device.
How often is GLP1 updated?
The latest version of GLP1 is 1.13, and it was last updated on September 24, 2026. Updates typically include new features and improvements.
What is the user sentiment for GLP1?
Based on the available data, GLP1 has a perfect rating of 5.0 stars from 1 rating, indicating very positive initial user sentiment.










